Spondyloarthritis & psoriatic arthritis
Impact of cardiometabolic comorbidities on clinical characteristics, prescription patterns and retention rate of first b/tsDMARD treatment in 5299 European real-world patients with psoriatic arthritis
Authors' conclusion
Cardiometabolic comorbidity burden, especially obesity, was associated with marginally lower treatment retention.
Study context
- Population
- Patients with PsA initiating a first b/tsDMARD in 2015 or later, eight European rheumatology registries, with information on five cardiometabolic comorbidities (obesity, dyslipidaemia, diabetes, hypertension, ischaemic heart disease) at baseline36% ≥1 comorbidity
- Participants
- 5,299 patients
- Exposure
- Cardiometabolic comorbidity burden and status
- Outcome
- Treatment retention of first b/tsDMARD
- Follow-up
- 12 months
Methodological detailsmulti-registry, eight European rheumatology registries, multivariable Cox regression, Kaplan-Meier, log-rank tests
- Multi-registry
- Eight European rheumatology registries
- Multivariable Cox regression
- Kaplan-Meier, log-rank tests
Main finding
As reported in the abstract
Treatment retention rate by comorbidity burden
Each group vs 0 comorbiditiesHazard ratio (95% CI)
≥2 comorbidities
1.18(0.98–1.42)
- 1 comorbidity
- HR 1.19 (95% CI 1.02–1.40)
Observational data: associations, not effects.
Further findings
IL-17 inhibitor use by comorbidity burden
JAKi use by comorbidity burden
| Outcome | P value |
|---|---|
| Treatment retention rate by obesity · 12 monthsObesity present vs Obesity absent | log-rank, p=0.04 |
- Treatment retention rate by obesity: Obesity absent 79%
- Treatment retention rate by obesity: Obesity present 77%
TNFi prescribed (all patients)
- Most patients prescribed TNFi regardless of comorbidity
- 76%
Baseline characteristics
- Patients with comorbidity were older, had higher disease activity and more disability
Original publication
Impact of cardiometabolic comorbidities on clinical characteristics, prescription patterns and retention rate of first b/tsDMARD treatment in 5299 European real-world patients with psoriatic arthritis. RMD Open. Published 7 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →